文献速递瓣膜外科

新型经心室搏动心脏二尖瓣修复系统的一年结局

Safety and performance of a novel transventricular beating heart mitral valve repair system: 1-year outcomes.
PubMed 文献 · Eur J Cardiothorac Surg · 2021-01-01

两项前瞻性多中心研究共纳入65例退行性二尖瓣反流患者,采用HARPOON搏动心脏二尖瓣修复系统植入ePTFE人工腱索。62例(95%)技术成功,主要终点(30天成功植入且反流≤中度)达成率91%。1年时2例死亡、8例再手术,52%患者无反流或微量反流,左心室重构指标改善。

要点

  • HARPOON系统搏动心脏植入ePTFE人工腱索,65例中95%技术成功,91%达主要终点。
  • 1年时98%存活置入患者NYHA I/II级,52%无反流或微量反流,23%轻度,23%中度,2%重度。
  • 1年时左室舒张末容积和直径显著减小,平均跨二尖瓣压差1.4±0.7 mmHg。

核心结论

  • HARPOON搏动心脏二尖瓣修复系统早期安全性和性能令人鼓舞。

研究设计与样本

  • 两项前瞻性多中心研究,分别纳入13例(首次人体)和52例受试者,共65例退行性二尖瓣反流患者。
  • 患者接受HARPOON搏动心脏二尖瓣修复系统治疗,超声心动图由独立核心实验室分析。

主要发现

  • 65例中62例(95%)技术成功,2例中转开放手术,1例手术终止。
  • 主要终点(30天成功植入人工腱索且二尖瓣反流≤中度)在59/65(91%)患者中达成。
  • 62例治疗患者平均手术时间2.1±0.5小时,至出院无死亡、卒中或肾衰竭事件。
  • 1年时62例中2例死亡(3%),8例(13%)需再次手术。
  • 1年时置入HARPOON人工腱索的患者中98%为NYHA I或II级;二尖瓣反流无反流/微量52%(n=27)、轻度23%(n=12)、中度23%(n=12)、重度2%(n=1)。

临床怎么用

  • 对于退行性二尖瓣反流患者,HARPOON搏动心脏修复系统可作为避免体外循环的候选术式,但需注意1年时13%再手术率。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The objective of this study was to evaluate the safety and performance of a novel, beating heart procedure that enables echocardiographic-guided beating heart implantation of expanded polytetrafluoroethylene (ePTFE) artificial cords on the posterior mitral leaflet of patients with degenerative mitral regurgitation. METHODS: Two prospective multicentre studies enrolled 13 (first-in-human) and 52 subjects, respectively. Patients were treated with the HARPOON beating heart mitral valve repair system. The primary (30-day) end point was successful implantation of cord(s) with mitral regurgitation reduction to ≤moderate. An independent core laboratory analysed echocardiograms. RESULTS: Of 65 patients enrolled, 62 (95%) achieved technical success, 2 patients required conversion to open surgery and 1 procedure was terminated. The primary end point was met in 59/65 (91%) patients. Among the 62 treated patients, the mean procedural time was 2.1 ± 0.5 h. Through discharge, there were no deaths, strokes or renal failure events. At 1 year, 2 of the 62 patients died (3%) and 8 (13%) others required reoperations. At 1 year, 98% of the patients with HARPOON cords were in New York Heart Association class I or II, and mitral regurgitation was none/trace in 52% (n = 27), mild in 23% (n = 12), moderate in 23% (n = 12) and severe in 2% (n = 1). Favourable cardiac remodelling outcomes at 1 year included decreased end-diastolic left ventricular volume (153 ± 41 to 119 ± 28 ml) and diameter (53 ± 5 to 47 ± 6 mm), and the mean transmitral gradient was 1.4 ± 0.7 mmHg. CONCLUSIONS: This initial clinical experience with the HARPOON beating heart mitral valve repair system demonstrates encouraging early safety and performance. CLINICAL REGISTRATION NUMBERS: NCT02432196 and NCT02768870.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gammie JS, Bartus K, Gackowski A, et al. Safety and performance of a novel transventricular beating heart mitral valve repair system: 1-year outcomes. Eur J Cardiothorac Surg. 2021. PMID: 33038223. doi:10.1093/ejcts/ezaa256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。